Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-07-11

FDA Approved: XYZAL ALLERGY 24HR — Supplemental Application (Chattem, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for XYZAL ALLERGY 24HR (levocetirizine dihydrochloride) filed by Chattem, Inc., related to a supplement to the exist…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XYZAL ALLERGY 24HR (LEVOCETIRIZINE DIHYDROCHLORIDE)

Snippet

SUPPL AP for XYZAL ALLERGY 24HR (LEVOCETIRIZINE DIHYDROCHLORIDE)